293 related articles for article (PubMed ID: 22889147)
1. Successful integrase inhibitor-based highly active antiretroviral therapy for a multidrug-class-resistant HIV type 1 group O-infected patient in Cameroon.
Aghokeng AF; Kouanfack C; Peeters M; Mpoudi-Ngole E; Delaporte E
AIDS Res Hum Retroviruses; 2013 Jan; 29(1):1-3. PubMed ID: 22889147
[No Abstract] [Full Text] [Related]
2. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.
Nguyen BY; Isaacs RD; Teppler H; Leavitt RY; Sklar P; Iwamoto M; Wenning LA; Miller MD; Chen J; Kemp R; Xu W; Fromtling RA; Vacca JP; Young SD; Rowley M; Lower MW; Gottesdiener KM; Hazuda DJ
Ann N Y Acad Sci; 2011 Mar; 1222():83-9. PubMed ID: 21434946
[TBL] [Abstract][Full Text] [Related]
3. [Raltegravir is the first HIV integrase inhibitor as part of antiretroviral treatment regimens].
Kravchenko AV
Ter Arkh; 2010; 82(11):27-32. PubMed ID: 21381345
[TBL] [Abstract][Full Text] [Related]
4. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
5. Raltegravir phase III study data released.
AIDS Patient Care STDS; 2008 Nov; 22(11):917. PubMed ID: 19043838
[No Abstract] [Full Text] [Related]
6. [Integrase inhibition].
Bogner JR
MMW Fortschr Med; 2009 Apr; 151(18):68-71. PubMed ID: 19769082
[No Abstract] [Full Text] [Related]
7. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
[TBL] [Abstract][Full Text] [Related]
8. Raltegravir. In HIV-infected in children at least 2 years of age. Only after prior treatment failure.
Prescrire Int; 2014 Sep; 23(152):206. PubMed ID: 25325117
[TBL] [Abstract][Full Text] [Related]
9. Raltegravir as effective as efavirenz in 144-week data.
AIDS Patient Care STDS; 2009 Aug; 23(8):679-80. PubMed ID: 19694035
[No Abstract] [Full Text] [Related]
10. Emergence of raltegravir-resistant HIV-1 in the central nervous system.
Watanabe K; Honda M; Watanabe T; Tsukada K; Teruya K; Kikuchi Y; Oka S; Gatanaga H
Int J STD AIDS; 2010 Dec; 21(12):840-1. PubMed ID: 21297097
[TBL] [Abstract][Full Text] [Related]
11. Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load.
Papendorp SG; van den Berk GE
AIDS; 2009 Mar; 23(6):739. PubMed ID: 19279447
[No Abstract] [Full Text] [Related]
12. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists.
Hughes A; Barber T; Nelson M
J Infect; 2008 Jul; 57(1):1-10. PubMed ID: 18556070
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance.
Mangiafico L; Perja M; Fusco F; Riva S; Mago D; Gringeri A
Haemophilia; 2012 Jan; 18(1):108-11. PubMed ID: 21762404
[TBL] [Abstract][Full Text] [Related]
14. Integrase inhibitors in the treatment of HIV-1 infection.
Powderly WG
J Antimicrob Chemother; 2010 Dec; 65(12):2485-8. PubMed ID: 20852268
[TBL] [Abstract][Full Text] [Related]
15. Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy.
Young B; Fransen S; Greenberg KS; Thomas A; Martens S; St Clair M; Petropoulos CJ; Ha B
Antivir Ther; 2011; 16(2):253-6. PubMed ID: 21447875
[TBL] [Abstract][Full Text] [Related]
16. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
[TBL] [Abstract][Full Text] [Related]
17. Use of raltegravir in a late presenter HIV-1 woman in advanced gestational age: case report and literature review.
De Hoffer L; Di Biagio A; Bruzzone B; Sticchi L; Prinapori R; Gerbaldo D; Gotta C; Viscoli C
J Chemother; 2013 Jun; 25(3):181-3. PubMed ID: 23783144
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral treatment update from the 17th International AIDS Conference.
Boyle B; Cohen C; DeJesus E; Elion R; Frank I; Moyle G; Sax P
AIDS Read; 2008 Nov; 18(11):570-9. PubMed ID: 19062402
[No Abstract] [Full Text] [Related]
19. Novel integrase inhibitors for HIV.
Prada N; Markowitz M
Expert Opin Investig Drugs; 2010 Sep; 19(9):1087-98. PubMed ID: 20707594
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
[No Abstract] [Full Text] [Related]
[Next] [New Search]
